Search Results 901-910 of 18371 for alopecia
Toxicity of prior therapy that has not recovered to ≤ Grade 1 or baseline (with the exception of any grade of alopecia and anemia not requiring transfusion ...
The purpose of this study is to explore the impact of Setmelanotide on obesity in patients with various specific rare genetic mutations. Participation ...
A Study to Describe Patterns of Treatment, Demographics, Clinical Characteristics, and Overall Survival in Patients with Unresectable or Metastatic Melanoma.
... alopecia, etc.). Patients who have an ongoing requirement for thyroid replacement therapy from prior exposure to a checkpoint inhibitor but who are ...
Any unrecovered toxicity reactions of CTCAE version 4.03 ≥ grade 1 caused by any previous therapy (excluding alopecia and neurotoxicity ≤ grade 2). QTcF ...
That team will include your surgeon, a couple of physical medicine and rehabilitation doctors, specifically one who specializes in amputations and another who ...
About this study. This phase II trial studies the side effects and how well ibrutinib works in treating patients with chronic lymphocytic leukemia who ...
infographic-achdlifelongcare-app-desktop-960-rev · National Doctors' Day is March 30! · About Mayo Clinic · Medical Professionals · Businesses · Students.
The purpose of this study is to evaluate quality of life over time in patients treated with CAR-T therapy compared with autologous and allogeneic stem cell ...
[MUSIC PLAYING]. Richard Berger, M.D., Ph.D., Orthopedics, Mayo Clinic: It was probably about eight or nine years ago that I finally pieced things together ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!